Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of EVER001 in proteinuric glomerular diseases
CTR20260886Phase 2Active
- Sponsor
- Ginkgo Bioworks
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ever001 in focal segmental glomerulosclerosis (FSGS), nephrosis, IgA nephropathy (IgAN), sponsored by Ginkgo Bioworks. Started Mar 2026; status: active.
02
Drugs
ever001
03
Conditions
focal segmental glomerulosclerosis (FSGS)nephrosisIgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20260886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260886.